https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46000 C and ABCB1_c.3435C > T were included in the final model, whereby CLSN38 reduced from 76.8 to 55.1%. Conclusion: The identified UGT1A3_c.31 T > C and ABCB1_c.3435C > T variants, from wild type to homozygous, were included in the final model for SN38 clearance.]]> Tue 08 Nov 2022 16:32:22 AEDT ]]> Immunomodulatory activities of pixatimod: Emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44951 Tue 08 Nov 2022 11:00:45 AEDT ]]> An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1606 Sat 24 Mar 2018 08:30:40 AEDT ]]>